2022-27014. Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice; renewal of Federal advisory committee.

    SUMMARY:

    The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2024, expiration date.

    DATES:

    Authority for the Cardiovascular and Renal Drugs Advisory Committee will expire on August 27, 2024 unless the Commissioner formally determines that renewal is in the public interest.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Joyce Yu, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, (301) 837-7126, CRDAC@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Pursuant to 41 CFR 102-3.65 and approval by the Department of Health and Human Services and by the General Services Administration, FDA is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee (the Committee). The Committee is a discretionary Federal advisory committee established to provide advice to the Commissioner. The Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which FDA has regulatory responsibility.

    The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cardiovascular and renal disorders and makes appropriate recommendations to the Commissioner.

    The Committee shall consist of a core of 11 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of cardiology, hypertension, arrhythmia, angina, congestive heart failure, diuresis, and biostatistics. Members will be invited to serve for overlapping terms of up to 4 years. Non-Federal members of this committee will serve as Special Government Employees, representatives, or Ex-Officio members. Federal members will serve as Regular Government Employees or Ex-Officios. The core of voting members may Start Printed Page 76198 include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting representative member who is identified with industry interests. There may also be an alternate industry representative.

    Further information regarding the most recent charter and other information can be found at https://www.fda.gov/​advisory-committees/​cardiovascular-and-renal-drugs-advisory-committee/​cardiovascular-and-renal-drugs-advisory-committee-charter or by contacting the Designated Federal Officer (see FOR FURTHER INFORMATION CONTACT ). In light of the fact that no change has been made to the committee name or description of duties, no amendment will be made to 21 CFR 14.100.

    This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app.). For general information related to FDA advisory committees, please visit us at https://www.fda.gov/​AdvisoryCommittees/​default.htm.

    Start Signature

    Dated: December 8, 2022.

    Lauren K. Roth,

    Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2022-27014 Filed 12-12-22; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
12/13/2022
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice; renewal of Federal advisory committee.
Document Number:
2022-27014
Dates:
Authority for the Cardiovascular and Renal Drugs Advisory Committee will expire on August 27, 2024 unless the Commissioner formally determines that renewal is in the public interest.
Pages:
76197-76198 (2 pages)
Docket Numbers:
Docket No. FDA 2022-N-3091
PDF File:
2022-27014.pdf
Supporting Documents:
» Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal
» Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal
» Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal